Cargando…

Government royalties on sales of biomedical products developed with substantial public funding

This paper proposes a policy of royalties paid to the government on the sales of biomedical products developed with public funds. The proposed policy would increase the incentives to create and to transfer to the private sector useful biomedical inventions from the research done in federal laborator...

Descripción completa

Detalles Bibliográficos
Autores principales: Danziger, Robert S., Scott, John T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7436069/
https://www.ncbi.nlm.nih.gov/pubmed/32836770
http://dx.doi.org/10.1007/s10961-020-09821-6
_version_ 1783572469051817984
author Danziger, Robert S.
Scott, John T.
author_facet Danziger, Robert S.
Scott, John T.
author_sort Danziger, Robert S.
collection PubMed
description This paper proposes a policy of royalties paid to the government on the sales of biomedical products developed with public funds. The proposed policy would increase the incentives to create and to transfer to the private sector useful biomedical inventions from the research done in federal laboratories and in universities. The royalties policy would also address the concern that taxpayers pay prices perceived to be unreasonable for biomedical products developed with substantial taxpayer funding.
format Online
Article
Text
id pubmed-7436069
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-74360692020-08-19 Government royalties on sales of biomedical products developed with substantial public funding Danziger, Robert S. Scott, John T. J Technol Transf Article This paper proposes a policy of royalties paid to the government on the sales of biomedical products developed with public funds. The proposed policy would increase the incentives to create and to transfer to the private sector useful biomedical inventions from the research done in federal laboratories and in universities. The royalties policy would also address the concern that taxpayers pay prices perceived to be unreasonable for biomedical products developed with substantial taxpayer funding. Springer US 2020-08-19 2021 /pmc/articles/PMC7436069/ /pubmed/32836770 http://dx.doi.org/10.1007/s10961-020-09821-6 Text en © Springer Science+Business Media, LLC, part of Springer Nature 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Article
Danziger, Robert S.
Scott, John T.
Government royalties on sales of biomedical products developed with substantial public funding
title Government royalties on sales of biomedical products developed with substantial public funding
title_full Government royalties on sales of biomedical products developed with substantial public funding
title_fullStr Government royalties on sales of biomedical products developed with substantial public funding
title_full_unstemmed Government royalties on sales of biomedical products developed with substantial public funding
title_short Government royalties on sales of biomedical products developed with substantial public funding
title_sort government royalties on sales of biomedical products developed with substantial public funding
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7436069/
https://www.ncbi.nlm.nih.gov/pubmed/32836770
http://dx.doi.org/10.1007/s10961-020-09821-6
work_keys_str_mv AT danzigerroberts governmentroyaltiesonsalesofbiomedicalproductsdevelopedwithsubstantialpublicfunding
AT scottjohnt governmentroyaltiesonsalesofbiomedicalproductsdevelopedwithsubstantialpublicfunding